Merck & Co. (MRK) — insider trading
Health Care · NYSE
Merck & Co. (MRK) has 121 reported SEC Form 4 insider transactions in our data, including 17 open-market sales among the most recent 100 (latest 2026-09-30).
Recent Form 4 transactions
Showing the 100 most recent of 121 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Seidman Christine E | Director | Grant / award / vesting (derivative) | 56 | $145.31 | $8.1K | Form 4 |
| 2026-09-30 | Karsanbhai Surendralal Lanca | Director | Grant / award / vesting (derivative) | 112 | $145.31 | $16.3K | Form 4 |
| 2026-09-30 | Coe Mary Ellen | Director | Grant / award / vesting (derivative) | 206 | $145.31 | $30.0K | Form 4 |
| 2026-08-13 | Guindo Chirfi | Officer (EVP, Access, Policy & Comms) | Open-market sale | 10,000 | $135.00 | $1.35M | Form 4 |
| 2026-08-12 | Zachary Jennifer | Officer (EVP, General Counsel) | Option exercise / conversion (derivative) | 13,433 | — | $0 | Form 4 |
| 2026-08-12 | Zachary Jennifer | Officer (EVP, General Counsel) | Option exercise / conversion (derivative) | 41,494 | — | $0 | Form 4 |
| 2026-08-12 | Zachary Jennifer | Officer (EVP, General Counsel) | Open-market sale | 80,315 | $133.46 | $10.72M | Form 4 |
| 2026-08-12 | Zachary Jennifer | Officer (EVP, General Counsel) | Option exercise / conversion | 13,433 | $84.71 | $1.14M | Form 4 |
| 2026-08-12 | Zachary Jennifer | Officer (EVP, General Counsel) | Option exercise / conversion | 41,494 | $117.89 | $4.89M | Form 4 |
| 2026-08-12 | DeLuca Richard R. | Officer (EVP&Pres, Merck Animal Heallth) | Open-market sale | 600 | $132.04 | $79.2K | Form 4 |
| 2026-08-12 | DeLuca Richard R. | Officer (EVP&Pres, Merck Animal Heallth) | Open-market sale | 11,099 | $131.61 | $1.46M | Form 4 |
| 2026-08-11 | DeLuca Richard R. | Officer (EVP&Pres, Merck Animal Heallth) | Open-market sale | 5,427 | $132.35 | $718.3K | Form 4 |
| 2026-08-11 | DeLuca Richard R. | Officer (EVP&Pres, Merck Animal Heallth) | Open-market sale | 7,410 | $131.33 | $973.2K | Form 4 |
| 2026-08-10 | DeLuca Richard R. | Officer (EVP&Pres, Merck Animal Heallth) | Open-market sale | 20,784 | $130.43 | $2.71M | Form 4 |
| 2026-08-06 | DeLuca Richard R. | Officer (EVP&Pres, Merck Animal Heallth) | Open-market sale | 300 | $131.02 | $39.3K | Form 4 |
| 2026-08-06 | DeLuca Richard R. | Officer (EVP&Pres, Merck Animal Heallth) | Open-market sale | 4,945 | $130.23 | $644.0K | Form 4 |
| 2026-08-06 | DeLuca Richard R. | Officer (EVP&Pres, Merck Animal Heallth) | Open-market sale | 805 | $131.02 | $105.5K | Form 4 |
| 2026-08-06 | Guindo Chirfi | Officer (EVP, Access, Policy & Comms) | Open-market sale | 15,000 | $131.00 | $1.97M | Form 4 |
| 2026-08-05 | Williams David Michael | Officer (EVP,Chief Info&Digital Officer) | Option exercise / conversion (derivative) | 34,705 | — | $0 | Form 4 |
| 2026-08-05 | Williams David Michael | Officer (EVP,Chief Info&Digital Officer) | Option exercise / conversion (derivative) | 13,542 | — | $0 | Form 4 |
| 2026-08-05 | Williams David Michael | Officer (EVP,Chief Info&Digital Officer) | Option exercise / conversion (derivative) | 4,600 | — | $0 | Form 4 |
| 2026-08-05 | Williams David Michael | Officer (EVP,Chief Info&Digital Officer) | Open-market sale | 34,705 | $128.77 | $4.47M | Form 4 |
| 2026-08-05 | Williams David Michael | Officer (EVP,Chief Info&Digital Officer) | Option exercise / conversion | 34,705 | $73.73 | $2.56M | Form 4 |
| 2026-08-05 | Williams David Michael | Officer (EVP,Chief Info&Digital Officer) | Open-market sale | 13,542 | $128.77 | $1.74M | Form 4 |
| 2026-08-05 | Williams David Michael | Officer (EVP,Chief Info&Digital Officer) | Option exercise / conversion | 13,542 | $75.36 | $1.02M | Form 4 |
| 2026-08-05 | Williams David Michael | Officer (EVP,Chief Info&Digital Officer) | Open-market sale | 4,600 | $128.77 | $592.3K | Form 4 |
| 2026-08-05 | Williams David Michael | Officer (EVP,Chief Info&Digital Officer) | Option exercise / conversion | 4,600 | $77.62 | $357.1K | Form 4 |
| 2026-08-05 | Maraldo David R. | Officer (EVP & Pres. MMD) | Option exercise / conversion (derivative) | 2,686 | — | $0 | Form 4 |
| 2026-08-05 | Maraldo David R. | Officer (EVP & Pres. MMD) | Option exercise / conversion (derivative) | 9,709 | — | $0 | Form 4 |
| 2026-08-05 | Maraldo David R. | Officer (EVP & Pres. MMD) | Option exercise / conversion (derivative) | 6,311 | — | $0 | Form 4 |
| 2026-08-05 | Maraldo David R. | Officer (EVP & Pres. MMD) | Open-market sale | 2,686 | $128.72 | $345.7K | Form 4 |
| 2026-08-05 | Maraldo David R. | Officer (EVP & Pres. MMD) | Option exercise / conversion | 2,686 | $84.71 | $227.5K | Form 4 |
| 2026-08-05 | Maraldo David R. | Officer (EVP & Pres. MMD) | Open-market sale | 9,709 | $128.72 | $1.25M | Form 4 |
| 2026-08-05 | Maraldo David R. | Officer (EVP & Pres. MMD) | Option exercise / conversion | 9,709 | $87.10 | $845.7K | Form 4 |
| 2026-08-05 | Maraldo David R. | Officer (EVP & Pres. MMD) | Open-market sale | 6,311 | $128.72 | $812.3K | Form 4 |
| 2026-08-05 | Maraldo David R. | Officer (EVP & Pres. MMD) | Option exercise / conversion | 6,311 | $73.73 | $465.3K | Form 4 |
| 2026-06-30 | Coe Mary Ellen | Director | Grant / award / vesting (derivative) | 233 | $128.50 | $30.0K | Form 4 |
| 2026-06-30 | Karsanbhai Surendralal Lanca | Director | Grant / award / vesting (derivative) | 126 | $128.50 | $16.2K | Form 4 |
| 2026-06-30 | Seidman Christine E | Director | Grant / award / vesting (derivative) | 63 | $128.50 | $8.1K | Form 4 |
| 2026-05-29 | BAKER DOUGLAS M JR | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Craig Pamela J. | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | GLOCER THOMAS H | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | LAVIZZO-MOUREY RISA J | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Mayo Stephen | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Rothman Paul | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | RUSSO PATRICIA F | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Seidman Christine E | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | THULIN INGE G | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Coe Mary Ellen | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Karsanbhai Surendralal Lanca | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-29 | Warden Kathy J | Director | Grant / award / vesting (derivative) | 1,853 | $118.72 | $220.0K | Form 4 |
| 2026-05-05 | Guindo Chirfi | Officer (EVP, Access, Policy & Comms) | Grant / award / vesting (derivative) | 19,402 | — | $0 | Form 4 |
| 2026-05-05 | Guindo Chirfi | Officer (EVP, Access, Policy & Comms) | Grant / award / vesting (derivative) | 6,628 | — | $0 | Form 4 |
| 2026-05-05 | Smart Dalton E. III | Officer (SVP Fin. - Global Controller) | Grant / award / vesting (derivative) | 5,045 | — | $0 | Form 4 |
| 2026-05-05 | Smart Dalton E. III | Officer (SVP Fin. - Global Controller) | Grant / award / vesting (derivative) | 2,298 | — | $0 | Form 4 |
| 2026-05-05 | Oosthuizen Johannes Jacobus | Officer (EVP, Oncology & Int?l) | Grant / award / vesting (derivative) | 31,044 | — | $0 | Form 4 |
| 2026-05-05 | Oosthuizen Johannes Jacobus | Officer (EVP, Oncology & Int?l) | Grant / award / vesting (derivative) | 10,605 | — | $0 | Form 4 |
| 2026-05-05 | Maraldo David R. | Officer (EVP & Pres. MMD) | Grant / award / vesting (derivative) | 21,731 | — | $0 | Form 4 |
| 2026-05-05 | Maraldo David R. | Officer (EVP & Pres. MMD) | Grant / award / vesting (derivative) | 7,424 | — | $0 | Form 4 |
| 2026-05-05 | Foard Brian | Officer (EVP, Specialty, Pharma, & ID) | Grant / award / vesting (derivative) | 31,044 | — | $0 | Form 4 |
| 2026-05-05 | Foard Brian | Officer (EVP, Specialty, Pharma, & ID) | Grant / award / vesting (derivative) | 35,351 | — | $0 | Form 4 |
| 2026-05-05 | Foard Brian | Officer (EVP, Specialty, Pharma, & ID) | Grant / award / vesting (derivative) | 10,605 | — | $0 | Form 4 |
| 2026-05-05 | Davis Robert M | Director, Officer (Chairman, CEO & President) | Grant / award / vesting (derivative) | 139,697 | — | $0 | Form 4 |
| 2026-05-05 | Davis Robert M | Director, Officer (Chairman, CEO & President) | Grant / award / vesting (derivative) | 47,724 | — | $0 | Form 4 |
| 2026-05-05 | DeLuca Richard R. | Officer (EVP&Pres, Merck Animal Heallth) | Grant / award / vesting (derivative) | 34,924 | — | $0 | Form 4 |
| 2026-05-05 | DeLuca Richard R. | Officer (EVP&Pres, Merck Animal Heallth) | Grant / award / vesting (derivative) | 11,931 | — | $0 | Form 4 |
| 2026-05-05 | Larson Betty D | Officer (EVP, Chief HR Officer) | Grant / award / vesting (derivative) | 23,283 | — | $0 | Form 4 |
| 2026-05-05 | Larson Betty D | Officer (EVP, Chief HR Officer) | Grant / award / vesting (derivative) | 7,954 | — | $0 | Form 4 |
| 2026-05-05 | Li Dean Y | Officer (Executive VP & President, MRL) | Grant / award / vesting (derivative) | 58,207 | — | $0 | Form 4 |
| 2026-05-05 | Li Dean Y | Officer (Executive VP & President, MRL) | Grant / award / vesting (derivative) | 19,885 | — | $0 | Form 4 |
| 2026-05-05 | Litchfield Caroline | Officer (EVP & CFO) | Grant / award / vesting (derivative) | 46,566 | — | $0 | Form 4 |
| 2026-05-05 | Litchfield Caroline | Officer (EVP & CFO) | Grant / award / vesting (derivative) | 15,908 | — | $0 | Form 4 |
| 2026-05-05 | Williams David Michael | Officer (EVP,Chief Info&Digital Officer) | Grant / award / vesting (derivative) | 13,582 | — | $0 | Form 4 |
| 2026-05-05 | Williams David Michael | Officer (EVP,Chief Info&Digital Officer) | Grant / award / vesting (derivative) | 4,640 | — | $0 | Form 4 |
| 2026-05-05 | Zachary Jennifer | Officer (EVP, General Counsel) | Grant / award / vesting (derivative) | 35,312 | — | $0 | Form 4 |
| 2026-05-05 | Zachary Jennifer | Officer (EVP, General Counsel) | Grant / award / vesting (derivative) | 12,064 | — | $0 | Form 4 |
| 2026-05-02 | Maraldo David R. | Officer (EVP & Pres. MMD) | Option exercise / conversion (derivative) | 552 | — | $0 | Form 4 |
| 2026-05-02 | Maraldo David R. | Officer (EVP & Pres. MMD) | Shares withheld for taxes / exercise cost | 159 | $112.16 | $17.8K | Form 4 |
| 2026-05-02 | Maraldo David R. | Officer (EVP & Pres. MMD) | Option exercise / conversion | 552 | $112.16 | $61.9K | Form 4 |
| 2026-05-02 | Smart Dalton E. III | Officer (SVP Fin. - Global Controller) | Option exercise / conversion (derivative) | 383 | — | $0 | Form 4 |
| 2026-05-02 | Smart Dalton E. III | Officer (SVP Fin. - Global Controller) | Shares withheld for taxes / exercise cost | 132 | $112.16 | $14.8K | Form 4 |
| 2026-05-02 | Smart Dalton E. III | Officer (SVP Fin. - Global Controller) | Option exercise / conversion | 383 | $112.16 | $43.0K | Form 4 |
| 2026-04-30 | Larson Betty D | Officer (EVP, Chief HR Officer) | Option exercise / conversion (derivative) | 11,350 | — | $0 | Form 4 |
| 2026-04-30 | Larson Betty D | Officer (EVP, Chief HR Officer) | Shares withheld for taxes / exercise cost | 5,143 | $110.95 | $570.6K | Form 4 |
| 2026-04-30 | Larson Betty D | Officer (EVP, Chief HR Officer) | Option exercise / conversion | 11,350 | $110.95 | $1.26M | Form 4 |
| 2026-04-30 | Smart Dalton E. III | Officer (SVP Fin. - Global Controller) | Option exercise / conversion (derivative) | 464 | — | $0 | Form 4 |
| 2026-04-30 | Smart Dalton E. III | Officer (SVP Fin. - Global Controller) | Shares withheld for taxes / exercise cost | 159 | $110.95 | $17.6K | Form 4 |
| 2026-04-30 | Smart Dalton E. III | Officer (SVP Fin. - Global Controller) | Option exercise / conversion | 464 | $110.95 | $51.5K | Form 4 |
| 2026-04-29 | Oosthuizen Johannes Jacobus | Officer (EVP, Oncology & Int?l) | Option exercise / conversion (derivative) | 1,377 | — | $0 | Form 4 |
| 2026-04-29 | Oosthuizen Johannes Jacobus | Officer (EVP, Oncology & Int?l) | Shares withheld for taxes / exercise cost | 679 | $110.03 | $74.7K | Form 4 |
| 2026-04-29 | Oosthuizen Johannes Jacobus | Officer (EVP, Oncology & Int?l) | Option exercise / conversion | 1,377 | $110.03 | $151.5K | Form 4 |
| 2026-04-29 | Davis Robert M | Director, Officer (Chairman, CEO & President) | Option exercise / conversion (derivative) | 13,300 | — | $0 | Form 4 |
| 2026-04-29 | Davis Robert M | Director, Officer (Chairman, CEO & President) | Shares withheld for taxes / exercise cost | 6,551 | $110.03 | $720.8K | Form 4 |
| 2026-04-29 | Davis Robert M | Director, Officer (Chairman, CEO & President) | Option exercise / conversion | 13,300 | $110.03 | $1.46M | Form 4 |
| 2026-04-29 | Litchfield Caroline | Officer (EVP & CFO) | Option exercise / conversion (derivative) | 3,935 | — | $0 | Form 4 |
| 2026-04-29 | Litchfield Caroline | Officer (EVP & CFO) | Shares withheld for taxes / exercise cost | 1,938 | $110.03 | $213.2K | Form 4 |
| 2026-04-29 | Litchfield Caroline | Officer (EVP & CFO) | Option exercise / conversion | 3,935 | $110.03 | $433.0K | Form 4 |
| 2026-04-29 | Larson Betty D | Officer (EVP, Chief HR Officer) | Option exercise / conversion (derivative) | 2,085 | — | $0 | Form 4 |
| 2026-04-29 | Larson Betty D | Officer (EVP, Chief HR Officer) | Shares withheld for taxes / exercise cost | 715 | $110.03 | $78.7K | Form 4 |
| 2026-04-29 | Larson Betty D | Officer (EVP, Chief HR Officer) | Option exercise / conversion | 2,085 | $110.03 | $229.4K | Form 4 |
Ask the chat about MRK's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Merck & Co. (MRK).
Last updated 2026-09-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.